Understanding Your Multiple Myeloma Lab Tests



This lab tracker booklet explains common tests for patients with multiple myeloma. This resource is not provided to replace discussions with your healthcare provider. Your healthcare providers are the most valuable resource for answering questions you may have regarding cancer, treatment, your health and your well-being.





This worksheet can serve as a personal record of your lab test results. Reference ranges—values that are considered normal in healthy individuals—are provided below as a guide. Note that these ranges vary among laboratories. The laboratory performing the test should provide you with the reference range associated with the test result. To learn more about each test, see the sections following the worksheets in this booklet. If you have any questions about your test results, do not hesitate to discuss them with your healthcare team. (Unless otherwise specified, the measurements below are for people age 18 and up.)

Complete Blood Cell (CBC) Count

| | | | | | | Date | es of lab | oratory | tests | | | | |
|---|--|-------|-----|------|-----------|----------|-----------|---------|---------|--------|-------|-----|------|
| | | MONTH | DAY | YEAR | MONTH | DAY | YEAR | MONTH | DAY | YEAR | MONTH | DAY | YEAR |
| | | | | | | | | | | | | | |
| Measurement | Reference Range | | | Ma | rk the to | est valu | es in th | e colum | n belov | w each | date | | |
| White blood cells (WBCs) ¹ | 3.4-9.6 X 10 ⁹ /L | | | | | | | | | | | | |
| Absolute Neutrophil Count (ANC) ² | 1.56-6.45 X 10 ⁹ /L | | | | | | | | | | | | |
| Red blood cells (RBCs) ¹ | Biological males: 4.35-5.65 X 10 ¹² /L Biological females: 3.92-5.13 X 10 ¹² /L | | | | | | | | | | | | |
| Hemocrit ¹ | Biological males: 38.3-48.6 percent Biological females: 35.5-44.9 percent: | | | | | | | | | | | | |
| Hemoglobin (Hgb) ¹ | Biological males: 13.2-16.6 g/dL Biological females: 11.6-15 g/dL | | | | | | | | | | | | |
| Platelets ¹ | Biological males: 135-317 X 10 ⁹ /L Biological females: 157-371 X 10 ⁹ /L | | | | | | | | | | | | |
| Leukocytes ³ | 3.4-9.6 X 10 ⁹ /L | | | | | | | | | | | | |
| Absolute Lymphocytes ⁴ | ≥15 years 1.18-3.74 x 10³/uL | | | | | | | | | | | | |
| Absolute Monocytes ⁴ | ≥15 years 0.24-0.82 x 10³/uL | | | | | | | | | | | | |
| Absolute Eosinophils ⁴ | ≥15 years 0.04-0.54 x 10 ³ /uL | | | | | | | | | | | | |
| Absolute Basophils ⁴ | ≥15 years 0.01-0.08 x 10³/uL | | | | | | | | | | | | |
| Blood urea nitrogen (BUN) ⁵ | Between 6 to 24 mg/dl | | | | | | | | | | | | |
| Creatine ⁶ | Biological males: 0.74-1.35 mg/dL Biological females: 0.59-1.04 mg/dL | | | | | | | | | | | | |
| Calcium ⁷ | 18-59 years: 8.6-10.0 mg/dL 60-90 years: 8.8-10.2 mg/dL | | | | | | | | | | | | |

Complete Blood Cell (CBC) Count

| | | | | | | Date | s of lab | oratory | tests | | | | |
|-----------------------------|-----------------|-------|-----|------|-----------|----------|-----------|---------|---------|--------|-------|-----|------|
| | | MONTH | DAY | YEAR | MONTH | DAY | YEAR | MONTH | DAY | YEAR | MONTH | DAY | YEAR |
| | | | | | | | | | | | | | |
| Measurement | Reference Range | | | Ma | rk the te | est valu | es in the | e colum | n below | each c | late | | |
| Glucose ⁸ | 70-140 mg/dL | | | | | | | | | | | | |
| Protein, Total ⁹ | 6.3-7.9 g/dL | | | | | | | | | | | | |
| Notes | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |

Other

| | | | | | | Date | s of lab | oratory | tests | | | | |
|--|---|-------|-----|------|-----------|----------|-----------|---------|---------|--------|-------|-----|------|
| | | MONTH | DAY | YEAR | MONTH | DAY | YEAR | MONTH | DAY | YEAR | MONTH | DAY | YEAR |
| | | | | | | | | | | | | | |
| Measurement | Reference Range | | | Ma | rk the te | est valu | es in the | e colum | n below | each d | late | | |
| Beta2-microglobulin (B2M) ¹⁰ | 1.21-2.70 mcg/mL | | | | | | | | | | | | |
| Lactate dehydrogenase (LDH) ¹¹ | Biological males: 135-225 U/L Biological females: 135- 214 U/L | | | | | | | | | | | | |
| Notes | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |

M Spike^{12, 13}

| | | | | | | Date | s of lab | oratory | tests | | | | |
|---|--|-------|-----|------|-----------|----------|-----------|---------|---------|----------|-------|-----|------|
| | | MONTH | DAY | YEAR | MONTH | DAY | YEAR | MONTH | DAY | YEAR | MONTH | DAY | YEAR |
| | | | | | | | | | | | | | |
| Measurement | Reference Range | | | Ma | rk the te | est valu | es in the | e colum | n below | v each c | late | | |
| Serum protein electrophoresis (SPEP) | Any M spike presence may be abnormal | | | | | | | | | | | | |
| Serum protein mass spectrometry (if applicable) | Any M spike presence may be abnormal | | | | | | | | | | | | |
| Notes | | • | | | | | | | | | | | |

Quantitative Immunoglobulins (Igs)

| | | | | | | Dat | es of la | boratory | / tests | | | | |
|-------------------|-----------------|-------|-----|------|-----------|----------|----------|----------|---------|--------|-------|-----|------|
| | | MONTH | DAY | YEAR | MONTH | DAY | YEAR | MONTH | DAY | YEAR | MONTH | DAY | YEAR |
| | | | | | | | | | | | | | |
| Measurement | Reference Range | | | Ma | ark the t | test val | ues in t | he colur | nn belo | w each | date | | |
| IgG ¹⁴ | 767-1,590 mg/dL | | | | | | | | | | | | |
| IgA ¹⁴ | 61-356 mg/dL | | | | | | | | | | | | |
| IgM ¹⁴ | 37-286 mg/dL | | | | | | | | | | | | |
| IgD ¹⁵ | ≤10 mg/dL | | | | | | | | | | | | |
| IgE ¹⁶ | ≤214 kU/L | | | | | | | | | | | | |
| Notes | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |

Serum Immunofixation (IFE)

| | | | | | Dat | es of lal | boratory | y tests | | | | |
|---|---|--|--|--|--|--|--|--|--|--|--|--|
| | MONTH | DAY | YEAR | MONTH | DAY | YEAR | MONTH | DAY | YEAR | MONTH | DAY | YEAR |
| | | | | | | | | | | | | |
| Reference Range | | | Ma | ark the 1 | test val | ues in tl | ne colur | nn belo | w each | date | | |
| Types: IgG, IgA, IgM, IgD, IgE, then kappa Iambda | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | Types: IgG, IgA, IgM, IgD, IgE, then kappa | Reference Range Types: IgG, IgA, IgM, IgD, IgE, then kappa | Reference Range Types: IgG, IgA, IgM, IgD, IgE, then kappa | Reference Range Types: IgG, IgA, IgM, IgD, IgE, then kappa | Reference Range Types: IgG, IgA, IgM, IgD, IgE, then kappa | Reference Range Types: IgG, IgA, IgM, IgD, IgE, then kappa | Reference Range Types: IgG, IgA, IgM, IgD, IgE, then kappa | Reference Range Types: IgG, IgA, IgM, IgD, IgE, then kappa | Reference Range Types: IgG, IgA, IgM, IgD, IgE, then kappa | Reference Range Types: IgG, IgA, IgM, IgD, IgE, then kappa | Reference Range Types: IgG, IgA, IgM, IgD, IgE, then kappa | Reference Range Types: IgG, IgA, IgM, IgD, IgE, then kappa |

Serum Free Light Chain Assay¹⁸

| Measurement Refe | | MONTH | DAY | YEAR | MONTH | DAY | YEAR | MONTH | DAY | YEAR | MONTH | DAY | YEAR |
|---|--------------|-------|-----|------|-----------|----------|-----------|----------|---------|--------|-------|-----|------|
| Measurement Refe | | | | | | | | | 2711 | TEAR | HONTH | DAI | TEAR |
| Measurement Refe | | | | | | | | | | | | | |
| | erence Range | | | Ma | ark the t | test val | ues in th | ne colun | nn belo | w each | date | | |
| Kappa free light chain 0.33-1. | .94 mg/dL | | | | | | | | | | | | |
| Lambda free light chain 0.57-2 | 2.63 mg/dL | | | | | | | | | | | | |
| Kappa/lambda free light chain ration 0.26-1 | .65 mg/dL | | | | | | | | | | | | |
| Notes | | | | | | | | | | | | | |

24-Hour Urine Analysis

| | | | | | Dat | es of lal | ooratory | tests | | | | |
|--------------------------------------|--|--|--|--|--|---|---|--|--|---|--|---|
| | MONTH | DAY | YEAR | MONTH | DAY | YEAR | MONTH | DAY | YEAR | MONTH | DAY | YEAR |
| | | | | | | | | | | | | |
| Reference Range | | | Ma | ark the t | est val | ues in tl | ne colun | nn belo | w each | date | | |
| <229 mg/24 hours | | | | | | | | | | | | |
| ≥500 mg | | | | | | | | | | | | |
| No monoclonal protein detected | | | | | | | | | | | | |
| Biological males: 97-137 mL/min | | | | | | | | | | | | |
| Biological females: 88-128 mL/min | | | | | | | | | | | | |
| <150 mg/d | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | <229 mg/24 hours ≥500 mg No monoclonal protein detected Biological males: 97-137 mL/min Biological females: 88-128 mL/min | Reference Range <229 mg/24 hours ≥500 mg No monoclonal protein detected Biological males: 97-137 mL/min Biological females: 88-128 mL/min | Reference Range <229 mg/24 hours ≥500 mg No monoclonal protein detected Biological males: 97-137 mL/min Biological females: 88-128 mL/min | Reference Range <229 mg/24 hours ≥500 mg No monoclonal protein detected Biological males: 97-137 mL/min Biological females: 88-128 mL/min | Reference Range <229 mg/24 hours ≥500 mg No monoclonal protein detected Biological males: 97-137 mL/min Biological females: 88-128 mL/min | Reference Range <229 mg/24 hours ≥500 mg No monoclonal protein detected Biological males: 97-137 mL/min Biological females: 88-128 mL/min | Reference Range <229 mg/24 hours ≥500 mg No monoclonal protein detected Biological males: 97-137 mL/min Biological females: 88-128 mL/min | MONTH DAY YEAR MONTH DAY YEAR MONTH Reference Range <229 mg/24 hours ≥500 mg No monoclonal protein detected Biological males: 97-137 mL/min Biological females: 88-128 mL/min | Reference Range <229 mg/24 hours ≥500 mg No monoclonal protein detected Biological males: 97-137 mL/min Biological females: 88-128 mL/min | MONTH DAY YEAR MONTH DAY YEAR MONTH DAY YEAR MONTH DAY YEAR Reference Range Mark the test values in the column below each <229 mg/24 hours ≥500 mg No monoclonal protein detected Biological males: 97-137 mL/min Biological females: 88-128 mL/min | MONTH DAY YEAR MONTH DAY YEAR MONTH DAY YEAR MONTH DAY YEAR MONTH Reference Range ✓229 mg/24 hours ≥500 mg No monoclonal protein detected Biological males: 97-137 mL/min Biological females: 88-128 mL/min | MONTH DAY YEAR MONTH DAY YEAR MONTH DAY YEAR MONTH DAY Reference Range C229 mg/24 hours ≥500 mg No monoclonal protein detected Biological males: 97-137 mL/min Biological females: 88-128 mL/min |

Minimal Residual Disease (MRD)²⁴

| | | | | | | Dat | es of la | borator | y tests | | | | |
|-------------|------------------------------------|-------|-----|------|---------|----------|-----------|----------|---------|--------|-------|-----|------|
| | | MONTH | DAY | YEAR | MONTH | DAY | YEAR | MONTH | DAY | YEAR | MONTH | DAY | YEAR |
| | | | | | | | | | | | | | |
| Measurement | Reference Range | | | Ma | ark the | test val | ues in tl | he colur | nn belo | w each | date | | |
| MRD | Any value above zero indicates MRD | | | | | | | | | | | | |
| Notes | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |

Additional Tests

| | | | | | | Date | s of lab | oratory | tests | | | | |
|-------------|-----------------|-------|-----|------|-----------|----------|-----------|---------|---------|----------|-------|-----|------|
| | | MONTH | DAY | YEAR | MONTH | DAY | YEAR | MONTH | DAY | YEAR | MONTH | DAY | YEAR |
| | | | | | | | | | | | | | |
| Measurement | Reference Range | | | Ma | rk the te | est valu | es in the | e colum | n belov | v each o | late | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| Notes | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |

Additional Tests

| | | | | | | Date | s of lab | oratory | tests | | | | |
|-------------|-----------------|-------|-----|------|-----------|----------|-----------|---------|---------|----------|-------|-----|------|
| | | MONTH | DAY | YEAR | MONTH | DAY | YEAR | MONTH | DAY | YEAR | MONTH | DAY | YEAR |
| | | | | | | | | | | | | | |
| Measurement | Reference Range | | | Ma | rk the te | est valu | es in the | colum | n belov | v each d | late | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| Notes | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |

Additional Tests

| | | | | | | Dutt | s of lab | STUDIE | 10313 | | | | |
|-------------|-----------------|-------|-----|------|-----------|----------|-----------|--------|---------|--------|-------|-----|------|
| | | MONTH | DAY | YEAR | MONTH | DAY | YEAR | MONTH | DAY | YEAR | MONTH | DAY | YEAR |
| | | | | | | | | | | | | | |
| Measurement | Reference Range | | | Ma | rk the te | est valu | es in the | colum | n below | each c | late | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| Notes | | | | | | | | | | | | | |
| Notes | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |

TEST INFORMATION

This section explains the tests listed in the booklet and what the lab values might tell you about your multiple myeloma, the impact of treatments, and possible side effects.

BLOOD TESTS



Complete blood count (CBC)¹

A CBC measures the number of red blood cells, white blood cells, and platelets in the blood. Your body produces blood cells in the bone marrow. The increase in myeloma cells in the bone marrow can crowd out normal cells, leading to low blood counts. Blood cell counts are carefully monitored to diagnose and track your multiple myeloma, as well as the effect of treatment.



RBC count¹

A low RBC count, also called anemia, can cause fatigue and weakness.



Hematocrit¹

This measures the proportion of RBCs to the fluid (or plasma) in your blood.



White blood cells (WBCs)1

WBCs help fight infections. Low levels of WBCs mean you are less able to fight infection.



Hemoglobin (Hgb)^{1,26}

Hemoglobin is a protein in RBCs that carries oxygen in the blood to all parts of your body.



Neutrophils²⁵

Neutrophils are a type of WBC responsible for much of the body's protection against infection. A reduction in neutrophils increases the risk for infection, which is why a neutrophil count is closely monitored throughout treatment.



Platelets¹

Platelets help your blood to clot.



Red blood cells (RBCs)²⁶

RBCs carry oxygen to body tissues. How much oxygen your body tissues get depends on how many RBCs you have and how well they work. The RBC count, hematocrit, and hemoglobin are all tests to measure the amount of RBCs in your blood.



Chemistry profile²⁷

A blood chemistry profile measures the level of different substances in your blood. Blood chemistry levels provide insight to the function of different organs (kidney, liver, etc) that multiple myeloma and its treatments may affect.

BLOOD TESTS

Blood urea nitrogen (BUN) serum⁵

BUN is a measure of the level of urea nitrogen in your blood. Elevated BUN levels may be a sign of kidney dysfunction.



Creatinine, serum²⁸

Creatinine is a waste product of creatine—a chemical made by the body to supply energy mainly to muscles. If kidney function is not normal, creatinine levels may be increased in your blood.



Calcium, total, serum^{7,29}

Calcium plays an important role in bone mineralization, blood clotting, as well as the proper functioning of the heart and nervous system. Elevated levels of calcium may be an indicator of bone damage due to multiple myeloma.



Glucose, serum³⁰

Blood sugar, or glucose, is the main sugar found in your blood. Your blood carries glucose to all of your body's cells to use for energy.



Protein, total, serum³¹

The level of protein in the blood is measured by a total serum protein test. Proteins are critical for cell and tissue growth. Abnormal protein levels can indicate many health conditions. This includes multiple myeloma, which can cause protein to build up abnormally.

Beta2-microglobulin (B2M), serum¹⁰

High levels of the B2M protein can mean the multiple myeloma is more advanced and may indicate a poor prognosis.

Serum protein electrophoresis (SPEP)^{32,33}

Also known as immunoglobulins (Igs), antibodies are proteins produced by your immune system. They target and neutralize foreign substances, such as viruses and bacteria. Each Ig is made up of smaller units called heavy and light chains. SPEP tests measure the amount of heavy chain monoclonal proteins made by myeloma cells. The results are plotted on a chart. The monoclonal protein spike, or an M spike, looks like a peak on the chart.



Quantitative immunoglobulin (QIg)33

While SPEP indicates how much monoclonal protein there is, a quantitative immunoglobin test is necessary to determine the Ig type.



IqG³⁴

IgG antibodies are widespread in the body. Your body uses IgG antibodies to fight bacterial and viral infections.



IgA³⁴

IgA antibodies are mainly present in body secretions. They are the chief antibodies in the mucous membranes of the gastrointestinal and respiratory tract, as well as in saliva and tears.



IgM³⁴

Your body produces IgM antibodies to help the immune system fight infections in the blood. They are the first or primary Ig produced following exposure to an antigen (a foreign substance).



IgD³⁴

The role of IgD is not completely understood, and IgD is not routinely measured.



IgE³⁴

These antibodies play a role in allergies and parasites.

Serum immunofixation (IFE)35

An IFE can confirm the results of an SPEP and identify the monoclonal proteins with more specificity.

Serum free light chain assay³⁶

Light chains are proteins made by plasma cells and can link together to form Igs. This test measures the number of free light chains, meaning those that are not part of a whole Ig. A higher than normal number of free light chains can indicate a plasma cell disorder.

Serum free kappa light chains³²

Multiple myeloma may be indicated by increased kappa free light chains and an increased kappa/lambda ratio.

Serum free lambda light chains³²

Multiple myeloma may be indicated by increased lambda free light chains and a decreased kappa/lambda ratio.

Serum free kappa/lambda ratio³²

An abnormal kappa/lambda ratio may indicate excess production of the kappa or lambda light chain due to multiple myeloma.

URINE TESTS



24-hour urine analysis^{37,38}

Urinalysis involves a number of tests—including physical, chemical, and microscopic tests—that detect and measure various compounds in your urine. This test offers a more accurate assessment than a random urine protein electrophoresis (UPEP) because by collecting the urine over 24 hours, it can account for changes in the composition of the urine throughout the day.



24-hour urine total protein¹⁹

Protein in urine typically comes from plasma. As the name implies, this test measures the total amount of protein urine collected over a 24-hour period. Higher than normal amounts can indicate a problem.



Urine protein electrophoresis38

A urine protein electrophoresis is a test that analyzes the proteins in a urine sample. This test can help with initial diagnosis and disease monitoring.



Urine immunofixation³⁹

Urine immunofixation can help identify light and heavy chain components of monoclonal proteins.

IMAGING TESTS



X-ray/bone survey^{40,41}

X-ray imaging creates pictures of the inside of your body. The images show the parts of your body in different shades of black and white. Since multiple myeloma will cause decreased bone density and appear as "punched-out" bone lesions, X-rays can help in the diagnosis.



Magnetic resonance imaging (MRI)12

MRI uses strong magnets and radio waves to look at organs and structures inside your body. Healthcare professionals use MRI scans to diagnose multiple myeloma. A contrast fluid called gadolinium may be injected into your vein so details are easier to see in the images. MRIs can be particularly helpful when someone living with multiple myeloma has bone pain but x-rays appear normal. MRIs can also be used to look at bone marrow.

PET scan¹²

PET scan is an imaging test that uses a radioactive substance to look for disease in the body. It can reveal the locations of cancer cells in different parts of the body. Radioactive glucose is put into your veins, which will be absorbed by cancer cells. Then, a special camera can detect the locations and activity of the cells.

BONE MARROW TESTS

Bone marrow aspirate and biopsy⁴²



These tests are used to diagnose, monitor, and evaluate the prognosis of multiple myeloma by sampling the cell types found in bone marrow.

Bone marrow is the soft tissue in our bones that produces blood cells. It's made up of a honeycomb network of fibers that are filled with liquid where blood cells grow.

A bone marrow aspiration uses a needle that goes into the honeycomb network to collect the fluid and cells so they can be examined under a microscope. A specialist will look at the number of each type of cell, how much they have matured, and their appearance.

A bone marrow biopsy collects a cylindrical core that preserves the honeycomb structure of the marrow.

In addition to all the things a specialist can check with an aspirate, a biopsy also allows them to check for something called cellularity. This is a measurement that looks at the volume of blood cells versus other kinds of cells such as fats. A bone marrow biopsy also helps specialists spot changes to the bone, such as osteoporosis and fibrosis.

Specialists can also use the samples collected during bone marrow aspirates and biopsies to conduct other tests.

CYTOGENETIC TESTING⁴³

Another important kind of testing for people with multiple myeloma is called cytogenetic testing. It involves looking at the genetics of your cancer cells by searching for changes in deoxyribonucleic acid (DNA), including broken, missing, extra, or rearranged chromosomes.



Karyotyping⁴⁴

Karyotyping is a traditional form of cytogenic testing that involves arranging, pairing, and organizing chromosomes to find abnormalities. In this technique, a bone marrow sample is taken and stained with special dyes so the chromosomes can be seen more easily. The person performing the test then takes pictures of the chromosomes, lining them up into pairs based on each chromosome's pattern of light and dark areas. Once they are identified and organized, the chromosomes are evaluated to see if there are the right number of each and if there are any structural issues.



Fluorescence in situ hybridization (FISH)44

FISH is another type of cytogenic testing. In this testing method, healthcare providers look for DNA sequences that represent abnormalities associated with multiple myeloma. A bone marrow sample is taken, and strands of DNA with chromosomal abnormalities are then added to the marrow. These strands are stained using fluorescent dyes so they can be easily located. If the bone marrow sample shares a matching DNA sequence with one of these fluorescent strands, the two will stick together, indicating the patient has those chromosomal abnormalities. FISH tests can find most of the same things as a karyotype test, but it can also find things that are too small to be seen with usual cytogenetic methods.

MINIMAL RESIDUAL DISEASE (MRD)44

After treatment, you may be tested to see whether any disease remains. If a small number of myeloma cells are detected in the body, that person is said to be MRD-positive, meaning they have minimal residual disease. If no cancer cells are detected, the person is MRD-negative. Some tests are better at finding cancer cells than others; however, particularly when there are not a lot of cells to spot. Healthcare professionals are always searching for tests that are more sensitive, meaning they are better able to detect cancer cells even at very low concentrations. Some people may have no physical symptoms but still have MRD. These tests are important because they can help predict relapse. There are several recommended methods to test for MRD. These use samples from bone marrow aspirates and biopsies.

MASS SPECTROMETRY^{13,46,47}



Mass spectrometry is a technique that determines the chemicals in a sample. It works by classifying ions in a sample by their mass and charge. In multiple myeloma, mass spectrometry can be used to take a very detailed look at what's in your blood. Importantly, mass spectrometry can determine when an M spike is due to myeloma or therapeutic monoclonal antibodies. Research suggests mass spectrometry might be as sensitive as bone marrow biopsies for testing MRD.

Questions to ask your healthcare team and notes to yourself

| 1 | |
|---|--|
| 1 | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

REFERENCES

- Complete blood count (CBC). Mayo Clinic. December 20, 2020. Accessed August 11, 2022. https://www.mayoclinic.org/tests-procedures/complete-blood-count/about/pac-20384919
- 2. Neutrophils. Cleveland Clinic. January 21, 2022. Accessed September 13, 2022. https://my.clevelandclinic.org/health/body/22313-neutrophils
- 9109 sample report 20180503 CBC with differential blood. Mayo Clinic Laboratories. Accessed August 11, 2022. https://www.mayocliniclabs.com/test-catalog/Overview/9109
- Test directory: WBC and differential. Diagnostic Laboratory Services. Accessed September 6, 2022. https://til.dlslab.com/ physicians/test-directory-view-test/?test=520
- Blood urea nitrogen (BUN) test. Mayo Clinic website. August 19, 2021. Accessed August 12, 2022. https://www.mayoclinic.org/tests-procedures/blood-urea-nitrogen/about/pac-20384821
- Creatinine clearance, serum and 24-hour urine. Mayo Clinic Laboratories. Accessed August 15, 2022. https://www.mayocliniclabs.com/test-catalog/Overview/615813
- 7. Calcium, total, serum. Mayo Clinic Laboratories. Accessed August 15, 2022. https://www.mayocliniclabs.com/test-catalog/overview/601514#Clinical-and-Interpretive
- 8. Glucose, random, serum. Mayo Clinic Laboratories. Accessed August 15, 2022. https://www.mayocliniclabs.com/test-catalog/Overview/89115
- 9. Protein, total, serum. Mayo Clinic Laboratories. Accessed August 15, 2022. https://www.mayocliniclabs.com/test-catalog/overview/8520#Clinical-and-Interpretive
- 10. Beta-2-microglobulin, serum. Mayo Clinic Laboratories. Accessed August 15, 2022. https://www.mayocliniclabs.com/test-catalog/overview/9234#Clinical-and-Interpretive.
- LDH test. Cleveland Clinic. Updated April 15, 2022. Accessed September 8, 2022. https://my.clevelandclinic.org/health/diagnostics/22736-lactate-dehydrogenase-ldh-test
- 12. Tests to find multiple myeloma. February 28, 2018. Accessed September 8, 2022. https://www.cancer.org/cancer/multiple-myeloma/detection-diagnosis-staging/testing.html
- 13. Derman BA, Stefka AT, Jiang K, et al. Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation. *Blood Cancer J.* 2021;11(2):19.
- Immunoglobulins (IgG, IgA, and IgM), serum. Mayo Clinic Laboratories. Accessed August 15, 2022. https://www.mayocliniclabs.com/test-catalog/overview/8156
- Immunoglobulin D (IgD), serum. Mayo Clinic Laboratories.
 Accessed August 15, 2022. https://www.mayocliniclabs.com/test-catalog/Overview/9272#Clinical-and-Interpretive
- 16. Immunoglobulin E (IgE), serum. Mayo Clinic Laboratories. Accessed August 15, 2022. https://www.mayocliniclabs.com/test-catalog/overview/8159#Clinical-and-Interpretive
- 17. Immunoglobin structure and classes. ThermoFisher Scientific. Accessed August 31, 2022. https://www.thermofisher.com/ca/en/home/life-science/antibodies-learning-center/antibodies-resource-library/antibody-methods/immunoglobulin-structure-classes.html
- 18. Immunoglobulin free light chains, serum. Mayo Clinic Laboratories. Accessed August 15, 2022. https://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/84190
- Protein, total, 24 hour, urine. Mayo Clinic Laboratories. Accessed August 15, 2022. https://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/8261

- 20. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. *The Lancet Oncology*. 2014;15(12).
- Immunofixation. Medscape. Updated July 14, 2021. Accessed September 13, 2022. https://emedicine.medscape.com/article/2086976-overview
- 22. Creatine clearance test. Mount Sinai New York. August 15, 2022. https://www.mountsinai.org/health-library/tests/creatinine-clearance-test
- 23. Protein electrophoresis, 24-hour urine. Labcorp. Accessed September 14, 2022. https://www.labcorp.com/tests/003368/protein-electrophoresis-24-hour-urine
- Kostopoulos IV, Ntanasis-Stathopoulos I, Gavriatopoulou M, Tsitsilonis OE, Terpos E. Minimal residual disease in multiple myeloma: current landscape and future applications with immunotherapeutic approaches. Front Oncol. 2020;10:860.
- 25. Low white blood cell counts (neutropenia). American Cancer Society. February 1, 2020. Accessed August 31, 2022. https://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/low-blood-counts/neutropenia.html
- RBC count information. Icahn School of Medicine at Mount Sinai. Accessed August 31, 2022. https://www.mountsinai.org/health-library/tests/rbc-count
- 27. NCI dictionary of cancer terms blood chemistry test. National Cancer Institute. Accessed September 8, 2022. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/blood-chemistry-test
- Creatine tests. Mayo Clinic. Accessed September 8, 2022. https://www.mayoclinic.org/tests-procedures/creatinine-test/about/pac-20384646
- 29. Multiple myeloma early detection, diagnosis, and staging.
 American Cancer Society. February 28, 2018. Accessed
 September 8, 2022. https://www.cancer.org/cancer/multiple-myeloma/detection-diagnosis-staging.html
- 30. Blood sugar. Medline Plus. Updated June 15, 2017. Accessed September 8, 2022. https://medlineplus.gov/bloodsugar.html
- 31. Total protein test. National Health Service. Updated July 4, 2022. Accessed September 8, 2022. https://www.nhs.uk/conditions/total-protein-test/
- 32. Serum free light chains. Testing.com. Updated November 9, 2021. Accessed September 9, 2022. https://www.testing.com/tests/serum-free-light-chains
- Tests to assess monoclonal protein. International Myeloma Foundation. Updated July 19, 2021. Accessed September 9, 2022. https://www.myeloma.org/monoclonal-protein-tests
- 34. Immunoglobulins IgA, IgG, IgM. Lab Tests Online. Updated November 9, 2021. Accessed September 9, 2022. https://www.testing.com/tests/immunoglobulins-iga-igg-igm/
- 35. Katzmann JA. Screening panels for monoclonal gammopathies: time to change. *Clin Biochem Rev.* 2009;30(3):105-111.
- 36. Free light chains. Medline Plus. Updated September 13, 2021. Accessed September 9, 2022. https://medlineplus.gov/lab-tests/free-light-chains/
- 37. Urinalysis. Medline Plus. January 16, 2021. Accessed September 9, 2022. https://medlineplus.gov/ency/article/003579.htm
- 38. Protein electrophoresis, 24-hour urine (UPEP). Quest Diagnostics. Accessed September 9, 2022. https://testdirectory.guestdiagnostics.com/test/test-detail/750/protein-electrophoresis-24-hour-urine-upep?cc=MASTER
- 39. Immunofixation (IFE), urine. Labcorp. Accessed September 9, 2022. https://www.labcorp.com/tests/123034/immunofixation-ife-urine

REFERENCES continued

- 40. X-rays. Medline Plus. Updated March 4, 2016. Accessed September 9, 2022. https://medlineplus.gov/xrays.html
- 41. Silbermann R, Roodman GD. Myeloma bone disease: pathophysiology and management. *J Bone Oncology*. 2013;2(2): 59-69.
- 42. Testing.com. Bone marrow aspiration and biopsy. Updated January 28, 2021. Accessed September 11, 2022. https://www.testing.com/tests/bone-marrow-aspiration-and-biopsy/
- National Institutes of Health. Definition of cytogenetics. Accessed September 11, 2022. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/cytogenetics
- 44. My Leukemia Team. What is cytogenetic testing and how does it work? May 7, 2021. Accessed September 11, 2022. https://www.myleukemiateam.com/resources/what-is-cytogenetic-testing-and-how-does-it-work

- 45. Leukemia and Lymphoma Society. Minimal residual disease. Accessed September 11, 2022. https://www.lls.org/sites/default/files/National/USA/Pdf/Publications/FS35_MRD_Final_2019.pdf
- 46. Broad Institute. What is mass spectrometry? Accessed September 11, 2022. https://www.broadinstitute.org/technology-areas/what-mass-spectrometry
- 47. Murray DL, Puig N, Kristinsson S, et al. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report. *Blood Cancer J.* 2021;11(2):24.

